Samchundang Pharma Plunges 27%, Kolon TissuGene Falls 29% on July 21 Over FDA Feedback and Failed Clinical Trial

Kolon-28.26%
According to Korea Exchange, Samchundang Pharma dropped 27.41% to 173,500 won on July 21 after receiving FDA Pre-ANDA feedback on its oral semaglutide generic, with investors noting the response did not confirm final approval pathways. Kolon TissuGene fell 29.90% to 42,900 won on the same day following news that its osteoarthritis gene therapy failed Phase 3 clinical trials.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments